Cite
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
MLA
Mol, L., et al. “A Prospective Monitoring of Fatal Serious Adverse Events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) Phase III Trial (CAIRO) in Patients with Advanced Colorectal Cancer.” Annals of Oncology, vol. 21, no. 2, Feb. 2010, pp. 415–18. EBSCOhost, https://doi.org/10.1093/annonc/mdp330.
APA
Mol, L., Koopman, M., Ottevanger, P. B., & Punt, C. J. A. (2010). A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer. Annals of Oncology, 21(2), 415–418. https://doi.org/10.1093/annonc/mdp330
Chicago
Mol, L., M. Koopman, P. B. Ottevanger, and C. J. A. Punt. 2010. “A Prospective Monitoring of Fatal Serious Adverse Events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) Phase III Trial (CAIRO) in Patients with Advanced Colorectal Cancer.” Annals of Oncology 21 (2): 415–18. doi:10.1093/annonc/mdp330.